Tracking Cathie Wood: Nearly a million shares dumped in a fire sale of Nextdoor, while increasing investment in AI healthcare

On Monday Eastern Time, after the US and Israel launched airstrikes against Iran, the US stock market experienced significant volatility but ended nearly flat. Indices opened sharply lower due to geopolitical tensions early in the session, but bargain hunting emerged multiple times, driving the market higher.

Against this backdrop, Cathie Wood's overnight trading continued her extreme 'weeding out the weak and keeping the strong' style. On this day, ARK’s selling targeted traditional community social platforms; on the buying side, funds were precisely allocated to generative biomedicine and gene editing sectors.

Buying focus: Directly targeting 'AI healthcare'

Amid intensifying market dynamics, the buying actions on March 2nd were highly streamlined, with the core logic pointing directly at the singularity of 'AI reshaping biomedicine.'

Cathie Wood made a significant one-day increase in holdings of the gene-editing leader $Intellia Therapeutics (NTLA.US)$ by adding 67,200 shares, while continuing to increase stakes in the generative biomedicine company $Generate Biomedicines (GENB.US)$ by purchasing an additional 28,400 shares.This represents ARK's most aggressive deployment in non-hardware tech fields currently. GENB’s core is using generative AI for protein design, while NTLA is a pioneer in CRISPR gene editing. The combination of these two signifies a leap from traditional 'laboratory trial-and-error' to 'precise design based on underlying computational power' in pharmaceutical R&D. While continuously cutting down on traditional medical hardware and diagnostic companies, 'Wooden Sister' concentrates her firepower on these AI healthcare leaders who master disruptive technologies, aiming to capture the next exponential growth curve.

Selling direction: Cutting SaaS companies

The selling side perfectly demonstrated ARK’s “venture capital-style” stop-loss art — if an asset’s business model is disproven or its growth stalls in the AI era, they immediately cut losses and leave.

Cathie Wood's firm aggressively sold shares of the community social platform in a single day $Nextdoor Holdings (NXDR.US)$ up to 995,800 shares, ranking at the top of the day's sell list.Following the significant reduction on February 27, ARK's selling of Nextdoor has escalated to a level akin to complete liquidation. In an era where AI algorithms are aggressively capturing user attention and reshaping ad distribution mechanisms, traditional social platforms tied to geographic communities are facing severe challenges in user stickiness and monetization bottlenecks. The inevitable move is to completely remove such assets, which lack 'core technology' catalysts, from the core investment portfolio.

In addition, Cathie Wood continues to heavily cut IT operations SaaS companies $PagerDuty (PD.US)$selling 91,600 shares, while also reducing holdings in enterprise service giants $Salesforce (CRM.US)$ by 197 shares, as well as in vertical healthcare SaaS leader $Veeva Systems (VEEV.US)$ by 262 shares.Overall, whether it's general-purpose PD and CRM or vertical-specific VEEV, the current market consensus is extremely harsh: if enterprise software cannot deliver immediate subscription revenue growth through AI Copilot, its high valuation system will face reevaluation. ARK’s continued selling represents a vote of no confidence in the monetization capabilities of traditional SaaS.

At the same time, genetic diagnostics company $Veracyte (VCYT.US)$ was reduced by 71,600 shares, along with the Kazakhstan fintech platform $Kaspi.kz (KSPI.US)$ 27,000 shares.Cathie Wood's reduction in VCYT reflects ARK's extreme focus within the healthcare sector, with capital shifting away from traditional genomic diagnostics to more explosive generative pharmaceuticals (GENB); while the reduction in KSPI represents a tactical withdrawal of funds from individual stocks in emerging markets.

Futubull's [Opportunities Page] has launched a feature to track celebrity portfolio opportunities! Choose from multiple celebrity portfolios, one-click follow the moves of top investors, precisely lock in high-quality stocks, and invest with greater confidence!

222K Views